Establishment of an Immune-Related Gene Signature for Risk Stratification for Patients with Glioma

Table 2

The hazard ratio of the five DE IRGs for evaluating the impact on gliomas’ survival.

	TCGA cohort				CGGA cohort
Genes	HR (95% CI)	5-year survival rates (%)			HR (95% CI)	5-year survival rates (%)
		Low	High	value		Low	High	value
VEGFA	4.03 (3.16-5.15)	67.20	20.38	<0.0001	2.62 (1.99-3.45)	67.40	33.70	2.383-12
SOCS3	4.26 (3.35-5.43)	65.60	23.85	<0.0001	3.70 (2.80-4.89)	71.40	30.20	<0.0001
THBS1	2.93 (2.31-3.72)	59.80	29.61	<0.0001	2.25 (1.71-2.97)	64.70	36.70	3.727-09
SPP1	3.80 (2.98-4.85)	65.50	24.27	<0.0001	2.21 (1.68-2.90)	63.50	38.30	1.421-08
TGFB2	4.64 (3.64-5.92)	67.60	21.93	<0.0001	2.26 (1.72-2.97)	65.00	37.60	6.757-09

TCGA: The Cancer Genome Atlas; CGGA: Chinese Glioma Genome Atlas; HR: hazard ratio; VEGFA: vascular endothelial growth factor A; SOCS3: suppressor of cytokine signaling 3; THBS1: thrombospondin 1; SPP1: secreted phosphoprotein 1; TGFB2: transforming growth factor beta 2; bold texts indicate statistically significant difference.